New heart test could replace risky drug during artery checkups

NCT ID NCT06273293

Knowledge-focused Sponsor: Fundación EPIC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at a new, drug-free method to measure blood flow after opening blocked heart arteries in people with multiple blockages. About 150 adults will get a standard pressure wire test plus a newer technique using contrast dye and nitroglycerin. The goal is to see if the simpler method works just as well and helps predict future heart problems over one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients \>18 years old and, * Patients with multivessel coronary artery disease (multivessel coronary artery disease will be considered the presence of significant stenosis in 2 or more first or second order vessels greater than 1.5 mm in diameter with an angiographic reduction of their diameter ≥50% by visual estimation) subsidiary of percutaneous coronary revascularization in at least one of them and, * Use of Navvus pressure microcatheter both for functional diagnosis and for post-PCI evaluation of the different vessels and, * Patients who have signed the Informed Consent. Exclusion Criteria: * Patients with intolerance or contraindication to adenosine. * Hemodynamically unstable patients, acute phase of a STEACS. * Patient with significant comorbidity with limited life expectancy. * Patients with the patient's express refusal to participate in the study. * Pregnant or breastfeeding female patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

4 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

New heart test could replace risky drug during artery checkups

What the study statuses mean